Trial Profile
A postmarketing study investigating the effect of natalizumab in French patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms BIONAT
- 27 Jun 2017 Results evaluating the relation between immunoglobulin levels and JC virus serology on multiple sclerosis patients, presented at the 3rd Congress of the European Academy of Neurology.
- 05 Dec 2015 New trial record